Literature DB >> 25673264

Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.

Zohreh Noaparast1, Seyed Jalal Hosseinimehr, Majid Piramoon, Seyed Mohammad Abedi.   

Abstract

AS1411, a 26-base guanine-rich oligonucleotide aptamer, has high affinity to nucleolin, mainly on tumor cell surfaces. In this study, a modified AS1411 was labeled with (99m)Tc and evaluated as a potential tumor-targeting agent for imaging. The AS1411 aptamer was conjugated with HYNIC and labeled with (99m)Tc in the presence a co-ligand. Radiochemical purity and stability testing of the (99m)Tc-HYNIC-AS1411 aptamer were carried out with thin layer chromatography and a size-exclusion column in normal saline and human serum. Cellular nucleolin-specific binding, cellular internalization in DU-145 cells, as high levels of nucleolin expression, were performed. Additionally, biodistribution in normal mice and DU-145 tumour-bearing mice was assessed. Radiolabeling of the aptamer resulted in a reasonable yield and radiochemical purity after purification. The aptamer was stable in normal saline and human serum, and cellular experiments demonstrated specific binding of the AS1411 aptamer to the nucleolin protein. Based on biodistribution assessment of (99m)Tc-HYNIC-AS1411, rapid blood clearance was seen after injection and it appears that the excretion route was via the urinary system at 1 h post-injection. Tumours also showed a higher accumulation of radioactivity with this labeled aptamer. (99m)Tc-AS1411 can be a potential tool for the molecular imaging of nucleolin-overexpressing cancers.

Entities:  

Keywords:  99mTc; AS1411; aptamer; nucleolin; targeting; tumor

Mesh:

Substances:

Year:  2015        PMID: 25673264     DOI: 10.3109/1061186X.2015.1009075

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  9 in total

1.  Investigating Efficacy of Three DNA-Aptamers in Targeted Plasmid Delivery to Human Prostate Cancer Cell Lines.

Authors:  Saeedeh Askarian; Niloofar Khandan Nasab; Seyed Hamid Aghaee-Bakhtiari; Mohammad Hassan Jafari Najaf Abadi; Reza Kazemi Oskuee
Journal:  Mol Biotechnol       Date:  2022-07-14       Impact factor: 2.860

2.  Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas.

Authors:  David Kryza; Frédéric Debordeaux; Laurent Azéma; Aref Hassan; Olivier Paurelle; Jürgen Schulz; Catherine Savona-Baron; Elsa Charignon; Pauline Bonazza; Jacqueline Taleb; Philippe Fernandez; Marc Janier; Jean Jacques Toulmé
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

3.  Aptamer-conjugated Magnetic Nanoparticles as Targeted Magnetic Resonance Imaging Contrast Agent for Breast Cancer.

Authors:  Mohammad Keshtkar; Daryoush Shahbazi-Gahrouei; Seyyed Mehdi Khoshfetrat; Masoud A Mehrgardi; Mahmoud Aghaei
Journal:  J Med Signals Sens       Date:  2016 Oct-Dec

Review 4.  Current Advances in Aptamers for Cancer Diagnosis and Therapy.

Authors:  Shin-Ichiro Hori; Alberto Herrera; John J Rossi; Jiehua Zhou
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

5.  99mTc-radiolabeled GE11-modified peptide for ovarian tumor targeting.

Authors:  Najmeh Rahmanian; Seyed Jalal Hosseinimehr; Ali Khalaj; Zohreh Noaparast; Seyed Mohammad Abedi; Omid Sabzevari
Journal:  Daru       Date:  2017-05-02       Impact factor: 3.117

6.  NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs.

Authors:  Tyler Sheetz; Joseph Mills; Anna Tessari; Megan Pawlikowski; Ashley E Braddom; Tasha Posid; Debra L Zynger; Cindy James; Valerio Embrione; Kareesma Parbhoo; Claudia Foray; Vincenzo Coppola; Carlo M Croce; Dario Palmieri
Journal:  Cancers (Basel)       Date:  2020-07-10       Impact factor: 6.639

Review 7.  Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging.

Authors:  Leila Hassanzadeh; Suxiang Chen; Rakesh N Veedu
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-15

8.  A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein.

Authors:  Hui Li; Juan Liu; Xiaojuan Xiao; Shuming Sun; Hui Zhang; Yibin Zhang; Weihua Zhou; Bin Zhang; Mridul Roy; Hong Liu; Mao Ye; Zi Wang; Feng Liu-Smith; Jing Liu
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-15       Impact factor: 8.886

Review 9.  Aptamers as Theragnostic Tools in Prostate Cancer.

Authors:  Carlos David Cruz-Hernández; Griselda Rodríguez-Martínez; Sergio A Cortés-Ramírez; Miguel Morales-Pacheco; Marian Cruz-Burgos; Alberto Losada-García; Juan Pablo Reyes-Grajeda; Imelda González-Ramírez; Vanessa González-Covarrubias; Ignacio Camacho-Arroyo; Marco Cerbón; Mauricio Rodríguez-Dorantes
Journal:  Biomolecules       Date:  2022-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.